Brief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
20/05/2026 12:07
May 20 (Reuters) - Skye Bioscience Inc SKYE.O: SKYE ANNOUNCES COHORT REVIEW COMMITTEE APPROVED OPENING OF COHORT 2 BASED ON FAVORABLE SAFETY DATA FROM FIRST FOUR PARTICIPANTS TREATED IN COHORT 1 SKYE BIOSCIENCE INC - CRC APPROVES ENROLLMENT IN COHORT 2 (600 MG IV) AFTER FAVORABLE SAFETY REVIEW OF COHORT 1 Source text: ID:nGNX4v4YTY Further company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsRCS - Redx Pharma Limited - Redx to Present Poster on RXC008 at UEG Week
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
Brief: Skye Bioscience Says John Sharp Resigns As CFO - SEC Filing
Brief: Skye Bioscience - Enters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments Iii - SEC Filing
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM